ORIN-1001 is under clinical development by Shanghai Fosun Pharmaceutical (Group) and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ORIN-1001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ORIN-1001 is under development for the treatment of advanced solid tumors including relapsed refractory triple-negative breast cancer, ER+ HER2- breast cancer, MYC+ breast cancer, hepatocellular carcinoma, prostate cancer, metastatic castration-resistant prostate cancer, pancreatic cancer, ovarian cancer, non-small cell lung cancer, esophageal cancer, idiopathic pulmonary fibrosis, human epidermal growth factor receptor 2 positive breast cancer (HER22+ breast cancer), colorectal cancer and kidney cancer (renal cell cancer). The drug candidate is a new chemical entity administered by oral route in the form of tablet. The drug candidate acts by targeting inositol requiring protein 1 (IRE1).
Shanghai Fosun Pharmaceutical (Group) overview
Shanghai Fosun Pharmaceutical (Group) (Fosun Pharma), a subsidiary of Shanghai Fosun High Technology (Group) Co Ltd, is a drug company that offers pharmaceutical products, medical diagnostic products and medical device products. The company’s pharmaceutical products are mainly applied in the treatment of metabolism and digestive system, cardiovascular system, blood system, central nervous system, anti-infection, anti-tumor, vaccine and raw material and intermediates. Fosun Pharma provides medical diagnostic products includes real time PCR detector, human papillomavirus assay kit, HBV quantitative reagent, and biofosun microorganism identification and susceptibility analysis system. The company’s research and development unit concentrates on therapeutic areas of metabolism and digestive system, blood system, cardiovascular system and central nervous system. Fosun Pharma is headquartered in Shanghai, China.
For a complete picture of ORIN-1001’s drug-specific PTSR and LoA scores, buy the report here.